Foamix Pharmaceuticals Ltd. (FOMX) Downgraded to Hold at Zacks Investment Research
Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Tuesday.
According to Zacks, “Foamix Pharmaceuticals Ltd. is a specialty pharmaceutical company. It develops and commercializes foam-based formulations acne, impetigo, and other skin conditions. The Company’s lead product candidates include FMX101, which has completed a dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo. It has operations primarily in the United States, Germany, and Israel. Foamix Pharmaceuticals Ltd. is headquartered in Rehovot, Israel. “
A number of other research firms have also recently weighed in on FOMX. Guggenheim reissued a “buy” rating and issued a $20.00 target price (up previously from $10.00) on shares of Foamix Pharmaceuticals in a research note on Saturday, August 13th. TheStreet raised shares of Foamix Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 2nd.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/11/foamix-pharmaceuticals-ltd-fomx-downgraded-to-hold-at-zacks-investment-research.html
Foamix Pharmaceuticals (NASDAQ:FOMX) traded down 3.77% on Tuesday, hitting $9.20. 86,870 shares of the company were exchanged. The stock has a 50 day moving average price of $9.34 and a 200 day moving average price of $7.55. Foamix Pharmaceuticals has a one year low of $5.48 and a one year high of $10.40. The firm’s market cap is $282.08 million.
Foamix Pharmaceuticals (NASDAQ:FOMX) last posted its earnings results on Wednesday, August 10th. The specialty pharmaceutical company reported ($0.27) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.25) by $0.02. The business earned $1.50 million during the quarter, compared to the consensus estimate of $1.10 million. Foamix Pharmaceuticals had a negative net margin of 1,201.01% and a negative return on equity of 21.87%. On average, equities research analysts forecast that Foamix Pharmaceuticals will post ($0.87) EPS for the current fiscal year.
Institutional investors have recently added to or reduced their stakes in the stock. Alpine Partners VI LLC purchased a new position in Foamix Pharmaceuticals during the second quarter worth approximately $109,000. LMR Partners LLP purchased a new position in Foamix Pharmaceuticals during the second quarter worth approximately $112,000. TFS Capital LLC purchased a new position in Foamix Pharmaceuticals during the second quarter worth approximately $222,000. Geode Capital Management LLC raised its position in Foamix Pharmaceuticals by 13.6% in the first quarter. Geode Capital Management LLC now owns 38,243 shares of the specialty pharmaceutical company’s stock worth $249,000 after buying an additional 4,574 shares during the period. Finally, Laurion Capital Management LP purchased a new position in Foamix Pharmaceuticals during the second quarter worth approximately $415,000. Hedge funds and other institutional investors own 46.37% of the company’s stock.
Foamix Pharmaceuticals Company Profile
Foamix Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea, impetigo and other skin conditions. The Company operates in the segment of development and commercialization of foam-based formulations.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Foamix Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.